Scarica l'app Stockscreener
387.11
0.01%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$387.15
Aprire:
$389.69
Volume 24 ore:
1.98M
Relative Volume:
1.19
Capitalizzazione di mercato:
$99.25B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
27.67
EPS:
13.99
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-2.58%
1M Prestazione:
-0.71%
6M Prestazione:
-24.43%
1 anno Prestazione:
-18.36%
Intervallo 1D:
$384.87
$390.66
Intervallo di 1 settimana:
$384.87
$398.29
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Czech National Bank Acquires 3,790 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Italy approves reimbursement for Vertex’s gene editing therapy CASGEVY By Investing.com - Investing.com Canada
Vertex Pharmaceuticals Secures Italian Reimbursement Agreement For Gene-Edited Therapy CASGEVY - Nasdaq
Vertex Pharmaceuticals (VRTX) Secures Italian Reimbursement for Gene-Edited Therapy - GuruFocus
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - Business Wire
Channel Wealth LLC Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Procyon Advisors LLC Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
This 12% Dividend Is on Sale as a $30 Bn 'Hidden' Move Sparks Buying Opportunity - Investing.com
Advisors Capital Management LLC Has $616,000 Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cim LLC Sells 2,719 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Intech Investment Management LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Plunges Around 24% in Six Months: How to Play the Stock - Yahoo Finance
How Recent FDA Approval Impacts the Valuation Story for Vertex Pharmaceuticals in 2025 - Yahoo Finance
New England Research & Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
MassMutual Private Wealth & Trust FSB Has $11.93 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lowered by Swedbank AB - MarketBeat
McAdam LLC Sells 1,679 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Stock Underperforming the S&P 500? - MSN
Strs Ohio Buys New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Belpointe Asset Management LLC Acquires 2,784 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Focus Partners Wealth - MarketBeat
Short Squeeze: Is Vertex Pharmaceuticals Incorporated currently under institutional pressureJuly 2025 Trends & AI Enhanced Market Trend Forecasts - khodrobank.com
Aug Setups: Should value investors consider GRFXTrade Risk Assessment & Stepwise Swing Trade Plans - خودرو بانک
Paladin Wealth LLC Purchases Shares of 1,240 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gradient Investments LLC Buys New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
E. Ohman J or Asset Management AB Has $4.68 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
GK Wealth Management LLC Purchases Shares of 689 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Modern Wealth Management LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fortis Capital Advisors LLC Makes New $850,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Plato Investment Management Ltd Has $2.86 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Aug Volume: Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Retail Activity & Stock Portfolio Risk Management - خودرو بانک
Ilmarinen Mutual Pension Insurance Co Buys 5,000 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CEO Moves: Is Vertex Pharmaceuticals Incorporated showing insider buyingBreakout Watch & Weekly Top Gainers Trade List - خودرو بانک
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals - The Globe and Mail
Voleon Capital Management LP Sells 7,475 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Zurich Insurance Group Ltd FI Purchases 158,379 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Integrity Alliance LLC. Makes New $445,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fred Alger Management LLC Has $6.46 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Peloton Wealth Strategists Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
NewEdge Advisors LLC Has $5.31 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Alaethes Wealth LLC Purchases Shares of 3,051 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
9,601 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by AG2R LA Mondiale Gestion D Actifs - MarketBeat
Voya Investment Management LLC Acquires 128,432 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Coppell Advisory Solutions LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Woodline Partners LP - MarketBeat
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.26%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):